The generic drugmaker listed $10 billion of debt and $10 billion of assets.
In calls and emails, TherapeuticsMD shared material, nonpublic information about a new drug's likelihood of FDA approval with sell-side analysts.
McKesson and Walgreens are strong, healthy companies, despite recent downturns in their stock prices, a CEO in the investment field says.
A jury verdict that held an ex-CFO liable for misleading investors makes clear that the SEC will take action against incomplete disclosures.
The ex-CFO of Aveo Pharmaceuticals and other top executives allegedly failed to disclose FDA concerns about an experimental cancer drug.
Mobile health apps are becoming more capable and potentially rather useful.
The Affordable Care Act's medical-device tax and a proposed Internet sales tax could rile CFOs in 2014.
Merck invests billions in drug R&spamp;D every year, and it&spamp;rsquo;s up to CFO Peter Kellogg to ensure that the money is spent wisely.
Despite one manufacturer’s staunch insistence that its broad coverage of alternative medicine practices yields big benefits, skeptics abound.
